Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
This approval addresses a significant gap in the market: weekly shots such as Wegovy and Eli Lillys Zepbound have dominated the anti-obesity market to date
However, the accelerated approval pathway means that evidence is still interim: while part one of the ESSENCE trial demonstrated improvement in liver scarring and inflammation, it does not yet show whether semaglutide reduces the risk of serious outcomes such as cirrhosis, liver failure or liver cancer
Tirzepatide does all of that and adds a second target, glucose-dependent insulinotropic polypeptide, or GIP
"Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials." Endocrine, Metabolic & Immune Disorders - Drug Targets
had some aluminium foil or something inside
doi: 10.1159/000442721 11 JaneAEpekMKlenJKunstGMaruiDRotar PavliDet al
